JP6178074B2 - ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 - Google Patents

ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 Download PDF

Info

Publication number
JP6178074B2
JP6178074B2 JP2012530248A JP2012530248A JP6178074B2 JP 6178074 B2 JP6178074 B2 JP 6178074B2 JP 2012530248 A JP2012530248 A JP 2012530248A JP 2012530248 A JP2012530248 A JP 2012530248A JP 6178074 B2 JP6178074 B2 JP 6178074B2
Authority
JP
Japan
Prior art keywords
ring system
nachr
agonist
halogen
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012530248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505282A5 (enExample
JP2013505282A (ja
Inventor
テレーズ・ディ・パオロ
ドミニク・フォイヤーバッハ
バルタサル・ゴメス−マンシラ
ドナルド・ジョーンズ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42990156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6178074(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013505282A publication Critical patent/JP2013505282A/ja
Publication of JP2013505282A5 publication Critical patent/JP2013505282A5/ja
Application granted granted Critical
Publication of JP6178074B2 publication Critical patent/JP6178074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012530248A 2009-09-22 2010-09-22 ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用 Active JP6178074B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24465809P 2009-09-22 2009-09-22
US61/244,658 2009-09-22
PCT/EP2010/063946 WO2011036167A1 (en) 2009-09-22 2010-09-22 Use of nicotinic acetylcholine receptor alpha 7 activators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015237921A Division JP2016104743A (ja) 2009-09-22 2015-12-04 ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用

Publications (3)

Publication Number Publication Date
JP2013505282A JP2013505282A (ja) 2013-02-14
JP2013505282A5 JP2013505282A5 (enExample) 2013-11-07
JP6178074B2 true JP6178074B2 (ja) 2017-08-09

Family

ID=42990156

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530248A Active JP6178074B2 (ja) 2009-09-22 2010-09-22 ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用
JP2015237921A Withdrawn JP2016104743A (ja) 2009-09-22 2015-12-04 ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015237921A Withdrawn JP2016104743A (ja) 2009-09-22 2015-12-04 ニコチン性アセチルコリン受容体アルファ７アクティベーターの使用

Country Status (22)

Country Link
US (3) US10537539B2 (enExample)
EP (1) EP2480228B1 (enExample)
JP (2) JP6178074B2 (enExample)
KR (1) KR20120068878A (enExample)
CN (2) CN102573830A (enExample)
AU (1) AU2010299967B2 (enExample)
BR (1) BR112012006346A2 (enExample)
CA (1) CA2774801C (enExample)
CL (1) CL2012000702A1 (enExample)
EA (1) EA036742B1 (enExample)
ES (1) ES2614930T3 (enExample)
IL (1) IL218299A (enExample)
JO (1) JO3250B1 (enExample)
MA (1) MA33590B1 (enExample)
MX (1) MX359011B (enExample)
NZ (1) NZ598316A (enExample)
PH (1) PH12012500554A1 (enExample)
SG (1) SG178832A1 (enExample)
TN (1) TN2012000082A1 (enExample)
TW (1) TWI558398B (enExample)
WO (1) WO2011036167A1 (enExample)
ZA (1) ZA201201066B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US20140171448A1 (en) * 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
EP2670744B1 (en) 2011-02-03 2015-05-27 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
AU2012221800B2 (en) 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
EA201391348A8 (ru) * 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
AU2012235779B2 (en) 2011-03-31 2017-03-02 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease
ES2606043T3 (es) 2011-07-05 2017-03-17 Lupin Limited Derivados de biarilo como moduladores de nAChR
IN2014CN03647A (enExample) * 2011-10-20 2015-10-09 Novartis Ag
WO2013132380A1 (en) 2012-03-06 2013-09-12 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
EP2945633B1 (en) * 2013-01-15 2021-06-30 Novartis AG Use of alpha 7 nicotinic acetylcholine receptor agonists
MX379289B (es) * 2013-01-15 2025-03-10 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
CN105636953B (zh) * 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
US20150313891A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use
ES2848322T3 (es) 2014-09-09 2021-08-06 Boehringer Ingelheim Animal Health Usa Inc Líneas celulares de mamífero que expresan receptores de acetilcolina funcionales de nematodos y uso de las mismas para ensayos de cribado de alto rendimiento
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
AU2016340798A1 (en) * 2015-10-20 2018-04-26 Axovant Sciences Gmbh Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102913697B1 (ko) 2019-02-05 2026-01-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR102925385B1 (ko) 2019-02-06 2026-02-11 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
US5746709A (en) 1996-04-25 1998-05-05 Medtronic, Inc. Intravascular pump and bypass assembly and method for using the same
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6908631B1 (en) * 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
DE69939498D1 (de) 1998-12-16 2008-10-16 Univ South Florida Exo-S-Mecamylamin-Formulierung
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
MXPA05001702A (es) 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004074245A2 (en) 2003-02-14 2004-09-02 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
JP2006519208A (ja) 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
WO2005044266A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
JP2007509935A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズｉｉ
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
KR20060125885A (ko) 2004-02-04 2006-12-06 뉴로서치 에이/에스 콜린 수용체 조절제로서의 디아자바이사이클릭 아릴 유도체
AU2005210039B2 (en) 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
RU2386633C2 (ru) 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
CA2584836A1 (en) 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008519820A (ja) 2004-11-15 2008-06-12 ファイザー・プロダクツ・インク Ｃｎｓ障害の治療のためのアザベンゾオキサゾール
WO2006051394A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
DE602005012722D1 (de) 2004-11-30 2009-03-26 Neurosearch As Neuartige diazabicyclische arylderivate als cholinerge liganden
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
JP2008530172A (ja) 2005-02-16 2008-08-07 ノイロサーチ アクティーゼルスカブ ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用
NZ560917A (en) 2005-03-31 2011-01-28 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
FR2884822B1 (fr) 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
WO2006116407A2 (en) 2005-04-22 2006-11-02 Cedars-Sinai Medical Center Compositions and methods for spinocerebellar ataxia
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
US8629163B2 (en) 2007-10-31 2014-01-14 University Of Kentucky Research Foundation Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
KR100688666B1 (ko) 2005-11-02 2007-03-02 엘지전자 주식회사 자동 오프 송수신 발광부를 갖는 무선 송신기, 무선텔레비전, 그리고 무선 텔레비전 시스템 및 그의 제어방법
WO2007056582A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
BRPI0620066A2 (pt) 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
WO2007085036A1 (en) 2006-01-26 2007-08-02 Medizinische Universität Wien Treatment of friedreich' s ataxia
US7662965B2 (en) 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
US20090075983A1 (en) 2006-02-14 2009-03-19 Dan Peters Novel Diazabicycloalkane Derivatives and Their Medical Use
EP1984351A1 (en) 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
KR20080104329A (ko) 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
CA2644448A1 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Varenicline standards and impurity controls
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
JP2009537599A (ja) 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用
WO2007135122A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
NZ571288A (en) 2006-05-30 2011-05-27 Neurosearch As Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
MX2008014885A (es) 2006-05-30 2008-12-05 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil pirimidinilo y su uso medico.
ES2498043T3 (es) 2006-06-06 2014-09-24 Cornerstone Therapeutics Inc. Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
US8178678B2 (en) 2006-06-16 2012-05-15 University Of Kentucky Research Foundation Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
AU2008216032A1 (en) 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6 ' substituted indole and indazole derivatives having 5-HT6 receptor affinity
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
KR20100031578A (ko) 2007-05-24 2010-03-23 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 갖는 4'-치환된 화합물
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009023844A2 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
KR101186704B1 (ko) 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
CN102007142A (zh) 2008-02-19 2011-04-06 麦欧赛普特股份有限公司 突触后靶向化学去神经剂及它们的使用方法
EP2271344A4 (en) 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
ES2392796T3 (es) 2008-04-17 2012-12-13 Proximagen Limited Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
JP2011520964A (ja) 2008-05-23 2011-07-21 ユニバーシティ・オブ・サウス・フロリダ ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法
US20100016297A1 (en) 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
WO2010043515A1 (en) 2008-10-13 2010-04-22 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
CN102209540A (zh) 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2012101424A (ru) 2009-06-17 2013-07-27 Таргасепт, Инк. Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途

Also Published As

Publication number Publication date
IL218299A (en) 2017-02-28
CA2774801C (en) 2017-11-28
ES2614930T3 (es) 2017-06-02
CA2774801A1 (en) 2011-03-31
US10537539B2 (en) 2020-01-21
CL2012000702A1 (es) 2012-09-14
ZA201201066B (en) 2012-10-31
JP2013505282A (ja) 2013-02-14
US20200108035A1 (en) 2020-04-09
MA33590B1 (fr) 2012-09-01
CN110051670A (zh) 2019-07-26
AU2010299967B2 (en) 2014-03-13
US11096916B2 (en) 2021-08-24
AU2010299967A1 (en) 2012-03-08
US20120172346A1 (en) 2012-07-05
MX2012003413A (es) 2012-04-30
US20210338621A1 (en) 2021-11-04
SG178832A1 (en) 2012-04-27
JO3250B1 (ar) 2018-09-16
MX359011B (es) 2018-09-12
TW201116534A (en) 2011-05-16
EP2480228B1 (en) 2016-11-16
NZ598316A (en) 2013-11-29
BR112012006346A2 (pt) 2017-05-23
WO2011036167A1 (en) 2011-03-31
CN102573830A (zh) 2012-07-11
PH12012500554A1 (en) 2012-10-22
US12678415B2 (en) 2026-07-14
TN2012000082A1 (en) 2013-09-19
CN110051670B (zh) 2026-05-01
EA201200507A1 (ru) 2012-10-30
KR20120068878A (ko) 2012-06-27
EA036742B1 (ru) 2020-12-15
EP2480228A1 (en) 2012-08-01
IL218299A0 (en) 2012-04-30
TWI558398B (zh) 2016-11-21
JP2016104743A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
US11096916B2 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
US20140171448A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
JP2015212277A (ja) 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
TWI659740B (zh) 阿法７菸鹼性乙醯膽鹼受體促效劑之用途
JP6031458B2 (ja) パーキンソン病におけるドーパミン誘発ジスキネジアに使用するためのアルファ７ニコチン性アセチルコリン受容体アクティベーターとｍＧｌｕＲ５アンタゴニストの組み合わせ剤
HK1172557A (zh) 烟碱乙酰胆碱受体α7激活剂的用途
HK1167081A (en) Use of nicotinic acetylcholine receptor alpha 7 activators
HK1167081B (en) Use of nicotinic acetylcholine receptor alpha 7 activators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130917

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140818

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170713

R150 Certificate of patent or registration of utility model

Ref document number: 6178074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250